نتایج جستجو برای: primary progressive ms

تعداد نتایج: 862134  

Journal: :Neurology 2004
S C J Huijbregts N F Kalkers L M J de Sonneville V de Groot I E W Reuling C H Polman

OBJECTIVE To investigate the cognitive skills of patients with relapsing remitting multiple sclerosis (RRMS), secondary progressive MS (SPMS), and primary progressive MS (PPMS) relative to healthy control subjects and to assess whether there is heterogeneity in the type of cognitive disabilities demonstrated by patients with different MS phenotypes. METHODS RRMS patients (n = 108), SPMS patie...

Journal: :Journal of neuroimmunology 2014
G Hassan-Smith L Durant A Tsentemeidou L K Assi J M Faint S Kalra M R Douglas S J Curnow

Cerebrospinal fluid (CSF) analysis is routinely used in the diagnostic work-up of multiple sclerosis (MS), by detecting CSF-specific oligoclonal bands (OCB). More recently, several studies have reported CSF free light chains (FLC) as an alternative. We show that absolute CSF κFLC concentrations were highly sensitive - more than OCB testing - and specific for clinically isolated syndrome, relaps...

Journal: :Arteriosclerosis, thrombosis, and vascular biology 2008
Philippe Giral Nelly Jacob Caroline Dourmap Boris Hansel Alain Carrié Eric Bruckert Xavier Girerd M John Chapman

BACKGROUND Prospective cohort studies have revealed that plasma gamma-glutamyltransferase (GGT) activity exhibits a positive association with coronary artery disease. GGT which is equally elevated in metabolic syndrome (MS), is the major regulator of circulating concentrations of thiol compounds derived from glutathione (GSH) cleavage, ie, cysteine and cysteinyl glycine. We compared the circula...

2014
Fozia Mir Donald Lee Hetal Ray Saud A. Sadiq

OBJECTIVE To investigate the potential of 8-iso-prostaglandin F2α (8-iso-PGF2α) as a biomarker for disease activity and oxidative stress in the CSF of patients with multiple sclerosis (MS). METHODS The isoprostane 8-iso-PGF2α is an established biomarker for in vivo oxidative stress and lipid peroxidation. We measured CSF 8-isoPGF2α levels in 231 patients with MS (74 with relapsing-remitting M...

2017
Rebecca Spain Katherine Powers Charles Murchison Elizabeth Heriza Kimberly Winges Vijayshree Yadav Michelle Cameron Ed Kim Fay Horak Jack Simon Dennis Bourdette

Objective: To determine whether lipoic acid (LA), an endogenously produced antioxidant, slowed the whole-brain atrophy rate and was safe in secondary progressive MS (SPMS). Methods: Patients with SPMS aged 40–70 years enrolled in a single center, 2-year, double-blind, randomized trial of daily oral 1,200mg LA vs placebo. Primary outcomewas change in annualized percent change brain volume (PCBV)...

Journal: :Psicothema 2013
Ma José Gil Moreno Marta Cerezo García Raluca Marasescu Ana Pinel González Laudino López Álvarez Yolanda Aladro Benito

BACKGROUND Cognitive impairment in multiple sclerosis (MS) is common (45-65%).Deficits occur in speed of information processing (SIP), memory, attention, executive functions (EF) and visuoconstruction.Involvement of cognitive functions like language and gnosis is rare and lesser known. Our aim is to describe the cognitive function and the clinical and radiological features of five patients with...

2016
Giulio Disanto Pascal Benkert Johannes Lorscheider Stefanie Mueller Jochen Vehoff Chiara Zecca Simon Ramseier Lutz Achtnichts Oliver Findling Krassen Nedeltchev Ernst-Wilhelm Radue Till Sprenger Christoph Stippich Tobias Derfuss Jean-François Louvion Christian P. Kamm Heinrich P. Mattle Christoph Lotter Renaud Du Pasquier Myriam Schluep Caroline Pot Patrice H. Lalive Özgür Yaldizli Claudio Gobbi Ludwig Kappos Jens Kuhle

The mechanisms leading to disability and the long-term efficacy and safety of disease modifying drugs (DMDs) in multiple sclerosis (MS) are unclear. We aimed at building a prospective cohort of MS patients with standardized collection of demographic, clinical, MRI data and body fluids that can be used to develop prognostic indicators and biomarkers of disease evolution and therapeutic response....

2005
Jack S. Burks

I. Introduction: In Multiple Sclerosis (MS) neither the pathogenesis of the disease nor the mechanism of an action of immunomodulating therapies (IMT " S) are fully understood [1,2,3]. Genetic predispositions, socioeconomic influences, gender (females: males = 2:1), infectious agents, and other environmental factors have been implicated [4,5]. Identifying treatment has been challenging since th...

Journal: :Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 2000
R D Henderson C J Bain M P Pender

The aims of this study were to determine whether the occurrence of autoimmune diseases is increased in patients with multiple sclerosis (MS) and their families and whether this is influenced by the type of MS. We conducted a case-control study using a questionnaire design to determine whether the prevalence of 11 autoimmune diseases is increased in patients with MS and their first-degree relati...

Journal: :AJNR. American journal of neuroradiology 2008
Z Liptak A M Berger M P Sampat A Charil O Felsovalyi B C Healy P Hildenbrand S J Khoury H L Weiner R Bakshi C R G Guttmann

BACKGROUND AND PURPOSE While brain MR imaging is routinely performed, the MR imaging assessment of spinal cord pathology in multiple sclerosis (MS) is less frequent in clinical practice. The purpose of this study was to determine whether measurements of medulla oblongata volume (MOV) on routine brain MR imaging could serve as a biomarker of spinal cord damage and disability in MS. MATERIALS A...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید